INSM Insmed Inc

Insmed INSM has outperformed the market over the past 10 years by 5.7% on an annualized basis producing an average annual return of 18.27%. Currently, Insmed has a market capitalization of $27.41 billion.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Needham raised I-Mab IMAB price target from $5 to $6. Needham analyst Gil Blum maintained a Buy rating.

Insmed's Brinsupri was approved as the first treatment for bronchiectasis in patients 12 and older. William Blair projects Insmed's peak sales could reach $15 billion by 2035. Get more market-moving news first with AI-powered analysis that turns noise into opportunity.

Legendary macro investor Stanley Druckenmiller made significant shifts in his portfolio in the second quarter, establishing major new positions in artificial intelligence and semiconductor leaders, rotating into large-cap banks, and placing a broadly bullish bet on the U.S. stock market, ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Guggenheim cut Eli Lilly and Company LLY price target from $942 to $875.

Brinsupri cuts annual NCFB exacerbations by up to 21% in Phase 3 trial. First FDA-approved treatment for 500,000 U.S. NCFB patients. This simple system has nailed 1,000+ post-earnings winners. Get in before Q3 trades take off → The U.S.